Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Alpha Tau (Nasdaq: DRTS) announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference on March 18, 2026 from 10:00–10:30 AM ET.

Rhea-AI Summary

Alpha Tau (Nasdaq: DRTS) announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference on March 18, 2026 from 10:00–10:30 AM ET. The presentation is virtual and Mr. Levy is available for one‑on‑one investor meetings scheduled through Sidoti representatives.

Market Context

This announcement highlights Alpha Tau’s participation in a virtual small-cap conference on March 18...

Analysis

This announcement highlights Alpha Tau’s participation in a virtual small-cap conference on March 18, 2026, with a 30‑minute presentation and 1x1 investor meetings. In context, the company recently reported Japanese marketing approval requiring a 66-patient surveillance study, positive PDAC data with ORR up to 23%, and full‑year 2025 results showing $76.9M cash and a $42.6M net loss. Investors would likely focus on how management updates these clinical, regulatory, and cash runway developments during the event.

Key Figures

Cash balance: $76.9M Net loss: $42.6M Objective response rate: 22% +5 more

Cash balance

$76.9M

Full-year 2025 results

Net loss

$42.6M

Full-year 2025 results

Objective response rate

22%

PDAC study overall ORR

Disease control rate

81%

PDAC study overall DCR

Patients enrolled

32 patients

Montreal first-in-human PDAC study

Objective response rate

23%

PDAC study excluding first two low‑dose patients

Disease control rate

87%

PDAC study excluding first two low‑dose patients

Post-market study size

66 patients

Japanese Alpha DaRT surveillance study across five centers

Historical Context

5 past events · Latest: Mar 09

5 events

1. Mar 09

   Full-year results

   24h Move

   +5.2%

   Reported 2025 results with cash balance, net loss and pipeline progress.

2. Feb 24

   Regulatory approval

   24h Move

   +1.7%

   Received Japanese marketing approval for Alpha DaRT in head and neck cancer.

3. Jan 29

   Corporate roadmap

   24h Move

   -9.1%

   Outlined five concurrent U.S. trials and key 2026 value-driving milestones.

4. Jan 06

   Clinical data update

   24h Move

   +9.3%

   Reported positive PDAC study results with meaningful ORR and DCR at ASCO GI.

5. Jan 05

   Regulatory submission

   24h Move

   +16.2%

   Submitted first PMA module to FDA for recurrent cSCC using modular pathway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026.

Event:	Sidoti Virtual Small Cap Conference
Format:	Company Presentation
Date:	March 18, 2026
Time:	10:00 – 10:30AM ET
Location:	Virtual

Mr. Levy will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule.

About Alpha Tau Medical Ltd. 

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT^®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Investor Relations Contact:
IR@alphatau.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Alpha Tau (DRTS) present at the Sidoti Virtual Small Cap Conference?

Alpha Tau will present on March 18, 2026, 10:00–10:30 AM ET. According to the company, CFO Raphi Levy will deliver the company presentation and be available for 1x1 investor meetings via Sidoti scheduling.

How can investors meet Alpha Tau CFO Raphi Levy at the Sidoti conference (DRTS)?

Investors can schedule 1x1 meetings through their Sidoti representative. According to the company, Raphi Levy will be available for one‑on‑one investor meetings during the virtual conference on March 18–19, 2026.

Where can I watch Alpha Tau's (DRTS) presentation at the Sidoti Virtual Small Cap Conference?

The presentation is being held in a virtual format on March 18, 2026 at 10:00 AM ET. According to the company, attendees should follow Sidoti conference access instructions or contact their Sidoti representative to join.

What topics will Alpha Tau (DRTS) cover in the Sidoti conference presentation?

The announcement states a company presentation by CFO Raphi Levy but gives no detailed agenda topics. According to the company, the session will cover corporate updates and investor engagement during the 30‑minute virtual presentation.

Is Alpha Tau's Sidoti presentation (DRTS) open to the public or by appointment?

The presentation is virtual and open via Sidoti conference access, while 1x1 meetings require scheduling through Sidoti representatives. According to the company, public attendance follows Sidoti registration and private meetings are by appointment.